5-甲基-6-苯基噻吩[2,3-D]嘧啶-4-醇 | 306934-76-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 5-甲基-6-苯基噻吩[2,3-D]嘧啶-4-醇
• 中文别名: 5-甲基-6-苯基噻吩并[2,3-D]嘧啶-4-醇
• 英文名称: 5-methyl-6-phenyl-3H-thieno[2,3-d]pyrimidin-4-one
• 英文别名: 5-methyl-6-phenylthieno[2,3-d]pyrimidin-4(3H)-one；5-methyl-6-phenylthieno[2,3-d]pyrimidin-4-ol
• CAS: 306934-76-9
• 化学式: C₁₃H₁₀N₂OS
• mdl: MFCD01935060
• 分子量: 242.301
• InChiKey: CTVQYCYDAHDMBF-UHFFFAOYSA-N

物化性质

• 熔点：
  247-249

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090

SDS

Name:	5-Methyl-6-phenylthieno[2 3-d]pyrimidin-4-ol 97% Material Safety Data Sheet
Synonym:	4-Hydroxy-5-methyl-6-phenylthienol[2,3-d]pyrimidin
CAS:	306934-76-9

Section 1 - Chemical Product MSDS Name:5-Methyl-6-phenylthieno[2 3-d]pyrimidin-4-ol 97% Material Safety Data Sheet
Synonym:4-Hydroxy-5-methyl-6-phenylthienol[2,3-d]pyrimidin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
306934-76-9	5-Methyl-6-phenylthieno[2,3-d]pyrimidi	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 306934-76-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 247 - 249 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H10N2OS
Molecular Weight: 242

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 306934-76-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Methyl-6-phenylthieno[2,3-d]pyrimidin-4-ol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 306934-76-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 306934-76-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 306934-76-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-6-苯基噻吩[2,3-D]嘧啶-4-醇 在 potassium fluoride dihydrate 、 三氯氧磷 作用下， 以 二甲基亚砜 为溶剂， 反应 5.25h， 生成
  参考文献：
  名称：

  人法呢基焦磷酸合酶基于硫代嘧啶的单膦酸酯（ThP-MP）抑制剂的药理学定位。

  摘要：

  人法呢基焦磷酸合酶（hFPPS）是甲羟戊酸途径中的关键调节酶，催化C-15异戊二烯类法呢基焦磷酸（FPP）的生物合成。FPP在执行大量细胞功能的小GTP酶的翻译后异戊烯化中起关键作用。尽管hFPPS是溶骨性疾病的公认治疗靶标，但目前可用的双膦酸酯类药物表现出不良的细胞摄取能力，并分布到非骨骼组织中。最近的药物发现工作主要集中在hFPPS的变构抑制和发现潜在用于治疗非骨骼疾病的非双膦酸酯药物上。一系列基于硫代嘧啶的单膦酸酯（ThP-MPs）的先导性优化导致鉴定出具有纳摩尔浓度抑制hFPPS的类似物。它们与酶的变构口袋的相互作用通过晶体学表征，并且结果提供了对变构抑制的药效团要求的进一步见解。

  DOI：

  10.1021/acs.jmedchem.6b01888
• 作为产物：
  描述：

  2-氨基-4-甲基-5-苯基-噻吩-3-甲酰胺 、 原甲酸三乙酯 反应 12.0h， 以85%的产率得到5-甲基-6-苯基噻吩[2,3-D]嘧啶-4-醇
  参考文献：
  名称：

  Thieno[2,3-d]pyrimidine als Glutamatantagonisten

  摘要：

  尽管Kainat受体在大脑中的功能目前尚未完全阐明，但它们在文献中越来越多地被定义为开发新型抗癫痫药物的新靶点。我们合成的噻吩并嘧啶类化合物被检测了其对Kainat受体亚型GluR5和GluR6的拮抗作用。效果最佳的是一种4-乙氧基噻吩并[2,3-d]嘧啶，它在GluR6受体上的IC50值为68 μM。

  DOI：

  10.1691/ph.2008.8600

文献信息

• Efficient Synthesis of14C-Labeled 1H-Pyrazolo[3,4-d]pyrimidine and Related [4.3.0]-Bicyclic Pyrimidino Systems
  作者：Jonathan Z. Ho、Kyle R. Van Arsdale、Matthew P. Braun

  DOI：10.1002/hlca.200890102

  日期：2008.5

  the readily available labeled starting material, sodium [14C]formate, has been developed with a good overall yield. This new method was proven to be general in the preparation of other related [4.3.0]heterocycles containing N, O, and S atoms. A concise synthesis of a model compound, 8-aza-7-deaza-5′-[14C]noraristeromycin, was achieved utilizing this methodology as a key step.

  为了支持旨在发现嘌呤相关抗癌药物候选物的研究计划，已开发了一种以易于获得的标记起始原料[ 14 C]甲酸钠为原料进行吡唑并嘧啶14 C标记的方法，该方法具有较高的总收率。事实证明，这种新方法在制备其他包含N，O和S原子的相关[4.3.0]杂环中是通用的。利用此方法作为关键步骤，可以完成模型化合物8-aza-7-deaza-5'-[ 14 C] noraristeromycin的简明合成。
• Thieno[2,3-d]pyrimidine als Glutamatantagonisten
  作者：Briel、Rybak、Kronbach、Unverferth

  DOI：10.1691/ph.2008.8600

  日期：——

  Obwohl die Funktion von Kainat-Rezeptoren im Hirn aktuell noch nicht vollständig geklärt ist, werden diese in der Literatur zunehmend als neue Zielobjekte bei der Entwicklung originärer Antiepileptika definiert. Die von uns synthetisierten Thienopyrimidine wurden auf eine antagonistische Wirkung an den Kainat-Rezeptor-Subtypen GluR5 und GluR6 untersucht. Die beste Wirkung erzielte ein 4-Ethoxy-thieno[2,3-d]pyrimidin mit einem IC50 von 68 μM am GluR6-Rezeptor. Thieno[2,3-d]pyrimidines as antagonists of the glutamate receptors Although the function of the kainate receptors in the brain is still not clear, they are increasingly defined as targets in the development of new classes of anti-epileptics. The thienopyrimidines described in this report were tested for their antagonistic effect at the kainate receptor subtypes GluR5 and GluR6. The highest effectiveness was obtained by a 4-ethoxy-thieno[2,3-d]pyrimidin with an IC50 = 68 μM at the GluR6 receptor.

  尽管Kainat受体在大脑中的功能目前尚未完全阐明，但它们在文献中越来越多地被定义为开发新型抗癫痫药物的新靶点。我们合成的噻吩并嘧啶类化合物被检测了其对Kainat受体亚型GluR5和GluR6的拮抗作用。效果最佳的是一种4-乙氧基噻吩并[2,3-d]嘧啶，它在GluR6受体上的IC50值为68 μM。
• Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase
  作者：Jaeok Park、Chun Yuen Leung、Alexios N. Matralis、Cyrus M. Lacbay、Michail Tsakos、Guillermo Fernandez De Troconiz、Albert M. Berghuis、Youla S. Tsantrizos

  DOI：10.1021/acs.jmedchem.6b01888

  日期：2017.3.9

  Recent drug discovery efforts have focused primarily on allosteric inhibition of hFPPS and the discovery of non-bisphosphonate drugs for potentially treating nonskeletal diseases. Hit-to-lead optimization of a new series of thienopyrimidine-based monosphosphonates (ThP-MPs) led to the identification of analogs with nanomolar potency in inhibiting hFPPS. Their interactions with the allosteric pocket of

  人法呢基焦磷酸合酶（hFPPS）是甲羟戊酸途径中的关键调节酶，催化C-15异戊二烯类法呢基焦磷酸（FPP）的生物合成。FPP在执行大量细胞功能的小GTP酶的翻译后异戊烯化中起关键作用。尽管hFPPS是溶骨性疾病的公认治疗靶标，但目前可用的双膦酸酯类药物表现出不良的细胞摄取能力，并分布到非骨骼组织中。最近的药物发现工作主要集中在hFPPS的变构抑制和发现潜在用于治疗非骨骼疾病的非双膦酸酯药物上。一系列基于硫代嘧啶的单膦酸酯（ThP-MPs）的先导性优化导致鉴定出具有纳摩尔浓度抑制hFPPS的类似物。它们与酶的变构口袋的相互作用通过晶体学表征，并且结果提供了对变构抑制的药效团要求的进一步见解。